Endocrine Rundowns: Ertugliflozin and Renal Outcomes


A nephrologist and professor from the University of Toronto offers insight into the results of a key kidney outcomes analysis of the VERTIS-CV trial.

In this edition of Endocrine Rundowns, David Cherney, MD, PhD, an associate professor from University of Toronto, discussing a renal outcomes analysis of the VERTIS-CV trial, which was originally presented at EASD 2020. A relative newcomer to the SGLT2 inhibitor class, VERTIS-CV offers the first glimpse into the renal effects of ertugliflozin in patients. In the interview, Cherney, dives deeper into the results of the trial and also breaks down how the enrollment criteria compared to other outcomes trials examining use of SGLT2 inhibitors.

Related Videos
Laxmi Mehta, MD | Credit: American Heart Association
Reviewing 2023 with FDA Commissioner Robert M. Califf, MD
Erin Michos, MD | Credit: Johns Hopkins University
Natalie McCormick, PhD | Credit: American College of Rheumatology
© 2024 MJH Life Sciences

All rights reserved.